US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
US6410802B1
(en)
|
1999-04-01 |
2002-06-25 |
Esperion Therapeutics, Inc. |
Methods for synthesizing ether compounds and intermediates therefor
|
US20090017069A1
(en)
*
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
US7407663B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
US7439052B2
(en)
*
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
AUPQ846900A0
(en)
*
|
2000-06-29 |
2000-07-27 |
Aruba International Pty Ltd |
A vaccine
|
US7407662B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
AU2007237157B2
(en)
*
|
2000-08-24 |
2009-04-09 |
The Regents Of The University Of California |
Peptides that ameliorate atherosclerosis
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US7166578B2
(en)
*
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
DE10051983A1
(de)
*
|
2000-10-20 |
2002-06-13 |
Beate Kehrel |
Inhibierung der pathogenen Wirkung oxidierter Proteine
|
BR0206273A
(pt)
|
2001-01-02 |
2006-11-21 |
Cleveland Clinic Foundation |
testes diagnósticos para caracterizar o risco de um paciente humano de desenvolver ou apresentar doença cardiovascular e para avaliar um agente terapêutico para doença cardiovascular em um sujeito suspeito de apresentar ou apresentando doença cardiovascular, e, kit
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US7217785B2
(en)
*
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
US20030127386A1
(en)
*
|
2001-06-25 |
2003-07-10 |
Bomberger David C. |
Hollow fiber contactor systems for removal of lipids from fluids
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
US20060060520A1
(en)
*
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
AU2002322284A1
(en)
*
|
2001-06-25 |
2003-01-08 |
Lipid Sciences, Inc. |
Systems and methods using multiple solvents for the removal of lipids from fluids
|
CA2451633C
(en)
*
|
2001-06-25 |
2010-11-30 |
Lipid Sciences, Inc. |
Systems and methods using a solvent for the removal of lipids from fluids
|
JP2005504085A
(ja)
*
|
2001-09-28 |
2005-02-10 |
エスペリオン セラピューティクス,インコーポレイテッド |
薬剤の局所投与による再狭窄の予防および治療
|
EP1438021A2
(en)
*
|
2001-09-28 |
2004-07-21 |
Esperion Therapeutics Inc. |
Methods and apparatus for extrusion of vesicles at high pressure
|
US6930085B2
(en)
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
BR0310099A
(pt)
*
|
2002-05-17 |
2007-03-20 |
Esperion Therapeutics Inc |
método para tratar dislipidemia ou uma doença associada com a dislipidemia
|
CN1668645A
(zh)
*
|
2002-05-17 |
2005-09-14 |
埃斯佩里安医疗公司 |
治疗缺血再灌注的方法和组合物
|
EP1545576A2
(en)
*
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Methods of using non-human animal apoliprotein a-i protein
|
EP1534243A4
(en)
*
|
2002-08-26 |
2008-08-13 |
Lipid Sciences Inc |
TREATMENT OF ALZHEIMER WITH ENTLIPIDED PROTEIN PARTICLES
|
US7335799B2
(en)
|
2003-01-23 |
2008-02-26 |
Esperion Therapeutics, Inc. |
Hydroxyl compounds and compositions for cholesterol management and related uses
|
AU2004233333A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Avanir Pharmacueticals |
Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
|
JP2007527387A
(ja)
*
|
2003-07-03 |
2007-09-27 |
リピッド サイエンシーズ,インコーポレイテッド |
脂質含量の低下したhdlの粒子誘導体を製造するための方法及び装置
|
US7393826B2
(en)
*
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
US7459286B1
(en)
*
|
2003-10-22 |
2008-12-02 |
The Cleveland Clinic Foundation |
Assessing the risk of a major adverse cardiac event in patients with chest pain
|
US6960803B2
(en)
*
|
2003-10-23 |
2005-11-01 |
Silicon Storage Technology, Inc. |
Landing pad for use as a contact to a conductive spacer
|
AU2004296829A1
(en)
*
|
2003-12-05 |
2005-06-23 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
AU2004299486B2
(en)
*
|
2003-12-15 |
2011-05-19 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
EP1699527A1
(en)
|
2004-01-02 |
2006-09-13 |
Advanced Cardiovascular Systems, Inc. |
High-density lipoprotein coated medical devices
|
JP2007531537A
(ja)
*
|
2004-04-06 |
2007-11-08 |
セダーズ−シナイ メディカル センター |
アポリポタンパク質a−iおよびアポリポタンパク質a−imilanoをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
|
WO2006020498A2
(en)
*
|
2004-08-11 |
2006-02-23 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
RU2448977C2
(ru)
*
|
2004-09-16 |
2012-04-27 |
Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье |
Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
|
WO2006049597A1
(en)
*
|
2004-10-27 |
2006-05-11 |
Avanir Pharmaceuticals |
Amino acid-derived compounds as modulators of the reverse cholesterol transport
|
AU2005314043A1
(en)
|
2004-12-06 |
2006-06-15 |
The Regents Of The University Of California |
Methods for improving the structure and function of arterioles
|
US20060160721A1
(en)
*
|
2004-12-22 |
2006-07-20 |
Baylor College Of Medicine |
Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
EP2269623A1
(en)
|
2005-04-29 |
2011-01-05 |
The Regents of The University of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
KR101577554B1
(ko)
|
2005-08-22 |
2015-12-14 |
멜리어 파마슈티칼스 아이, 인코포레이티드 |
Lyn 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
CN101489577B
(zh)
*
|
2006-06-01 |
2013-10-16 |
蒙特利尔心脏病学研究所 |
治疗心瓣膜病的方法和化合物
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
EP2041174A2
(en)
*
|
2006-06-16 |
2009-04-01 |
Lipid Sciences, Inc. |
Novel peptides that promote lipid efflux
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
CA2659655A1
(en)
|
2006-08-08 |
2008-02-21 |
Alan M. Fogelman |
Salicylanilides enhance oral delivery of therapeutic peptides
|
US20080138284A1
(en)
*
|
2006-09-26 |
2008-06-12 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
US8541236B2
(en)
*
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
WO2008094905A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Lipid Sciences, Inc. |
Encapsulated hdl mimetic peptides
|
CA2931881C
(en)
*
|
2007-01-31 |
2018-12-11 |
Nutrition 21, Inc. |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
KR20100014480A
(ko)
*
|
2007-02-20 |
2010-02-10 |
멜리어 파마슈티칼스 아이, 인코포레이티드 |
Lyn 키나제 활성제의 확인 방법
|
PL2465519T3
(pl)
|
2007-03-01 |
2014-05-30 |
Csl Ltd |
Leczenie dysfunkcji śródbłonka u pacjentów z cukrzycą
|
EP3050568B1
(en)
|
2007-03-13 |
2020-12-02 |
JDS Therapeutics, LLC |
Methods and compositions for the sustained release of chromium
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
NZ579288A
(en)
*
|
2007-07-23 |
2012-06-29 |
Melior Discovery Inc |
Methods of activating irs-1 and akt
|
DK2195331T3
(da)
|
2007-08-28 |
2014-02-03 |
Uab Research Foundation |
Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
US8044021B2
(en)
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
US8101565B2
(en)
*
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
US9173890B2
(en)
*
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
US8241861B1
(en)
|
2008-07-08 |
2012-08-14 |
Insilicos, Llc |
Methods and compositions for diagnosis or prognosis of cardiovascular disease
|
KR102344392B1
(ko)
|
2008-11-10 |
2021-12-28 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
AU2010208035B2
(en)
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
SI2396017T1
(sl)
|
2009-02-16 |
2015-12-31 |
Cerenis Therapeutics Holding Sa |
Mimika apolipoproteina A-1
|
NZ594995A
(en)
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
NZ621981A
(en)
|
2009-05-05 |
2015-09-25 |
Tekmira Pharmaceuticals Corp |
Lipid compositions
|
EA201791744A3
(ru)
|
2009-06-10 |
2018-07-31 |
Арбутус Биофарма Корпорэйшн |
Улучшенная липидная композиция
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
US20120270771A1
(en)
*
|
2009-09-30 |
2012-10-25 |
Snu R&Db Foundation |
Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
|
WO2011044545A2
(en)
|
2009-10-09 |
2011-04-14 |
Sigalov Alexander B |
Methods and compositions for targeted imaging
|
US9687550B2
(en)
|
2009-12-07 |
2017-06-27 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011143362A1
(en)
|
2010-05-11 |
2011-11-17 |
Esperion Therapeutics, Inc. |
Dimeric oxidation-resistant apolipoprotein a1 variants
|
US20130158055A1
(en)
|
2010-05-28 |
2013-06-20 |
Andrew G. Reaume |
Prevention Of Pancreatic Beta Cell Degeneration
|
DK2575764T3
(en)
|
2010-06-03 |
2017-08-07 |
Alnylam Pharmaceuticals Inc |
BIODEGRADABLE LIPIDS FOR THE ACTIVATION OF ACTIVE AGENTS
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
RU2013111678A
(ru)
|
2010-08-30 |
2014-10-10 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
|
CN103370054A
(zh)
|
2010-11-09 |
2013-10-23 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
EP2663548B1
(en)
|
2011-01-11 |
2017-04-05 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
CN103443123B
(zh)
|
2011-02-07 |
2020-05-29 |
塞勒尼斯医疗控股公司 |
脂蛋白复合物及其制备和用途
|
US8933022B2
(en)
|
2011-03-01 |
2015-01-13 |
Jds Therapeutics, Llc |
Methods and compositions for the treatment and prevention Hypoglycemia and related disorders
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
WO2013090319A2
(en)
|
2011-12-12 |
2013-06-20 |
Melior Pharmaceuticals I, Inc. |
Treatment of type i and type ii diabetes
|
CN103073646A
(zh)
*
|
2012-03-13 |
2013-05-01 |
华中科技大学 |
一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
US10017551B2
(en)
|
2013-03-15 |
2018-07-10 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
EP2853259A1
(en)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Reconstituted high density lipoproteins composition and uses thereof
|
RU2016144908A
(ru)
|
2014-05-02 |
2018-06-05 |
Серени Терапеутикс Холдинг Са |
Маркеры hdl-терапии
|
WO2016011049A2
(en)
*
|
2014-07-14 |
2016-01-21 |
Schwendeman Anna |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
EP3189069A4
(en)
|
2014-07-31 |
2018-03-07 |
UAB Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
US10307491B2
(en)
|
2015-01-30 |
2019-06-04 |
The Regents Of The University Of Michigan |
Liposomal particles comprising biological molecules and uses thereof
|
CA2978204A1
(en)
|
2015-03-13 |
2016-09-22 |
Esperion Therapeutics, Inc. |
Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
AU2016238290B9
(en)
|
2015-03-25 |
2019-06-13 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
MX2018009748A
(es)
|
2016-02-11 |
2019-02-07 |
Nutrition 21 Llc |
Composiciones que contienen cromo para mejorar la salud y el estado físico.
|
US11027052B2
(en)
|
2017-11-22 |
2021-06-08 |
HDL Therapuetics, Inc. |
Systems and methods for priming fluid circuits of a plasma processing system
|
CA3059432A1
(en)
|
2017-04-10 |
2018-10-18 |
Melior Pharmaceuticals I, Inc. |
Compositions comprising a lyn kinase activator and a trpms agonist
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
CARGOMÈRES
|
JP2021509894A
(ja)
|
2017-12-28 |
2021-04-08 |
エイチディーエル セラピューティクス インコーポレイテッドHdl Therapeutics, Inc. |
ヒト血漿から抽出されたpre−β高密度リポタンパク質を保存および投与するための方法
|
EP3986859A1
(en)
|
2019-06-21 |
2022-04-27 |
Esperion Therapeutics, Inc. |
Methods of making bempedoic acid and compositions of the same
|
CN115427064A
(zh)
|
2020-04-16 |
2022-12-02 |
阿比奥尼克斯制药公司 |
使用基于脂质结合蛋白的复合物治疗急性病况的方法
|
US20240000948A1
(en)
|
2020-10-01 |
2024-01-04 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
EP4322746A1
(en)
|
2021-04-15 |
2024-02-21 |
Abionyx Pharma SA |
Use of lipid binding protein-based complexes in organ preservation solutions
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
WO2023194798A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
|
WO2023237927A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
|
WO2023237935A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|